Segment Information

9 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Segment Information

13. Segment Information

We operate under two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight®. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.

Our Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; repackages generic pharmaceuticals and over the counter healthcare products; and includes our managed services organization platforms.

Our GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical, and laboratory products known as national brand products to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada.

The remaining three operating segments included in Other are Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics. These operating segments respectively operate nuclear pharmacies and radiopharmaceutical manufacturing facilities, distribute medical products to patients' homes in the United States, and provide supply chain services and solutions to our customers.

Revenue

The following tables present revenue for the two reportable segments and disaggregated revenue within the remaining operating segments, included in Other, and Corporate:

	Three Months Ended March 31,
(in millions)	2025		2024
Pharmaceutical and Specialty Solutions	$	50,433	$	50,622
Global Medical Products and Distribution	3,160		3,113
Nuclear and Precision Health Solutions	403		352
at-Home Solutions	817		730
OptiFreight® Logistics	84		72
Other	1,304		1,154
Total segment revenue	54,897		54,889
Corporate (1)	(19)		(21)
Total revenue	$	54,878	$	54,868

	Nine Months Ended March 31,
(in millions)	2025		2024
Pharmaceutical and Specialty Solutions	$	149,272	$	154,412
Global Medical Products and Distribution	9,437		9,272
Nuclear and Precision Health Solutions	1,148		1,006
at-Home Solutions	2,391		2,136
OptiFreight® Logistics	234		198
Other	3,773		3,340
Total segment revenue	162,482		167,024
Corporate (1)	(63)		(64)
Total revenue	$	162,419	$	166,960

(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

The following tables present revenue by geographic area:

	Three Months Ended March 31,
(in millions)	2025		2024
United States	$	54,498	$	54,464
International	399		425
Total segment revenue	54,897		54,889
Corporate (1)	(19)		(21)
Total revenue	$	54,878	$	54,868

	Nine Months Ended March 31,
(in millions)	2025		2024
United States	$	161,247	$	165,783
International	1,235		1,241
Total segment revenue	162,482		167,024
Corporate (1)	(63)		(64)
Total revenue	$	162,419	$	166,960

(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Segment Profit

We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less     segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate technology and shared function expenses, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.

We do not allocate the following items to our segments:

•last-in first-out, or ("LIFO"), inventory charges/(credits);

•state opioid assessment related to prior fiscal years;

•shareholder cooperation agreement costs;

•restructuring and employee severance;

•amortization and other acquisition-related costs;

•acquisition-related cash and share-based compensation costs;

•impairments and (gain)/loss on disposal of assets, net; we recognized a pre-tax goodwill impairment charge of $90 million during the three months ended March 31, 2024 and $675 million during the nine months ended March 31, 2024;

•litigation (recoveries)/charges, net;

•other (income)/expense, net;

•interest expense, net;

•loss on early extinguishment of debt; or

•provision for/(benefit from) income taxes

In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $15 million and $17 million for the three months ended March 31, 2025 and 2024, respectively, and $42 million and $37 million for the nine months ended March 31, 2025 and 2024, respectively.

The following tables present segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:

	Three Months Ended March 31,
(in millions)	2025		2024
Pharmaceutical and Specialty Solutions	$	662	$	582
Global Medical Products and Distribution	39		22
Other (1)	134		110
Total segment profit	835		714
Corporate	(105)		(345)
Total operating earnings	$	730	$	369

	Nine Months Ended March 31,
(in millions)	2025		2024
Pharmaceutical and Specialty Solutions	$	1,723	$	1,533
Global Medical Products and Distribution	65		45
Other (1)	356		312
Total segment profit	2,144		1,890
Corporate	(297)		(1,048)
Total operating earnings	$	1,847	$	842

(1)Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics.

Segment Assets

The following table presents total assets for the two reportable segments and the remaining operating segments, included in Other, and Corporate:

(in millions)	March 31, 2025		June 30, 2024
Pharmaceutical and Specialty Solutions	$	35,734	$	29,149
Global Medical Products and Distribution	7,201		7,047
Other (1)	2,726		2,606
Corporate	4,210		6,319
Total assets	$	49,871	$	45,121